Krystal Biotech, Inc.
KRYS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.15 | 3.57 | -1.69 | 0.37 |
| FCF Yield | 0.74% | 1.28% | 0.48% | 1.16% |
| EV / EBITDA | 114.09 | 74.96 | 129.49 | 97.06 |
| Quality | ||||
| ROIC | 1.24% | 4.40% | 2.98% | 4.05% |
| Gross Margin | 0.00% | 90.93% | 94.30% | 94.57% |
| Cash Conversion Ratio | 0.50 | 1.38 | 0.87 | 1.16 |
| Growth | ||||
| Revenue 3-Year CAGR | 252.00% | 7,108,446.21% | 6,934,300.77% | 6,622,914.24% |
| Free Cash Flow Growth | -25.32% | 105.23% | -52.41% | -9.98% |
| Safety | ||||
| Net Debt / EBITDA | -9.45 | -7.29 | -7.91 | -7.86 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.28 | 0.17 | 0.19 |
| Cash Conversion Cycle | 119.29 | 351.62 | 593.51 | 494.84 |